The basics of PET molecular imaging in neurodegenerative disorders with dementia and/or parkinsonism

1

Neurodegenerative diseases are increasingly defined by biological mechanisms, focusing on proteinopathies and the identification of biomarkers for early diagnosis.
2

PET imaging biomarkers are essential for understanding neurodegenerative disorders, enabling earlier and more accurate detection and diagnosis.
3

Amyloid PET imaging can detect amyloid pathology years before clinical symptoms of Alzheimer's disease appear, facilitating early intervention.
4

Fluorine-18 labeled amyloid PET tracers are widely used, providing high sensitivity and specificity for detecting amyloid plaques in cognitive impairment.
5

The review aims to standardize PET imaging practices in neurodegenerative disorders, addressing image interpretation and potential pitfalls.

1